FindTrial
Sign In

Comparison of terbinafine 250 mg and terbinafine 500 mg tablet in the treatment of tinea corporis and tinea cruris

Comparative Efficacy and Safety Of 250mg Versus 500mg Oral Terbinafine In The Treatment Of Tinea Corporis And Tinea Cruris: A, Randomized, Investigator-Blinded Pilot Clinical Trial From Eastern India

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/07/015131
Enrollment
60
Registered
2018-07-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- tinea corporis and tinea cruris

Interventions

Intervention1: Terbinafine 250 mg: Terbinafine 250 mg tablet for oral intake once daily Control Intervention1: Terbinafine 500mg: Terbinafine 500mg tablet for oral intake once daily

Sponsors

no nsuch
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients with extensive tinea corporis/cruris who are off treatment for the last 1 month will be included.

Exclusion criteria

Exclusion criteria: non consenting patients and Patients whose routine investigations reveal deranged LFT will be excluded from the study patients.

Design outcomes

Primary

MeasureTime frame
improvement in signs and symptoms of each clinical parameter, namely itching, erythema, papules, pustules, vesicles and scalingTimepoint: improvement in signs and symptoms of each clinical parameter, namely itching, erythema, papules, pustules, vesicles and scaling at 2 week and again at 4 week from the initiation of treatment—

Secondary

MeasureTime frame
adverse effects of higher dose terbinafineTimepoint: at 2 weeks and again at 4 weeks—

Countries

India

Contacts

Public ContactDr Abanti Saha

Department of Dermatology, medical college, Kolkata

sahaaby@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026